BMC Pulmonary Medicine (Sep 2024)

Analytical validation of the LungLB test: a 4-color fluorescence in-situ hybridization assay for the evaluation of indeterminate pulmonary nodules

  • Michelle L. Lutman,
  • Daniel Gramajo-Leventon,
  • Shahram Tahvilian,
  • Lara Baden,
  • Courtney L. Gilbert,
  • Michael Trejo,
  • Eric Vail,
  • Michael J. Donovan,
  • Benjamin A. Katchman,
  • Paul C. Pagano

DOI
https://doi.org/10.1186/s12890-024-03280-7
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Evaluation of indeterminate pulmonary nodules (IPNs) often creates a diagnostic conundrum which may delay the early detection of lung cancer. Rare circulating genetically abnormal cells (CGAC) have previously demonstrated utility as a biomarker for discriminating benign from malignant small IPNs in the LungLB assay. CGAC are identified using a unique 4-color fluorescence in-situ hybridization (FISH) assay and are thought to reflect early cell-based events in lung cancer pathogenesis and the anti-tumor immune response. LungLB is a prognostic tool that combines the CGAC biomarker and clinical features to aid in IPN evaluation by improving the stratification of patient risk of malignancy. Methods Herein we describe the analytical performance of the LungLB blood test. Analytical validation was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines with adaptations for rare cell-based assays. Multiple operators, reagent lots, and assay runs were tested to examine accuracy, precision, reproducibility, and interfering factors. Results The FISH probes used in the LungLB assay demonstrate 100% sensitivity and specificity for their intended chromosomal loci (3q29, 3p22.1, 10q22.3 and 10cen). LungLB demonstrates analytical sensitivity of 10 CGAC per 10,000 lymphocytes analyzed, 100% analytical specificity, and high linearity (R 2 = 0.9971). Within run measurements across 100 samples demonstrated 96% reproducibility. Interfering factors normally found in blood (lipemia, biotin) and exposure to adverse temperatures (-20ºC or 37ºC) did not interfere with results. Sample stability was validated to 96 hours. Conclusion The analytical performance of LungLB in this validation study successfully demonstrates it is robust and suitable for everyday clinical use.

Keywords